Change Of Plasma Level Of CRP And TNF-α In Recurrent Patients With Hepatocellular Carcinoma Before/after PMCT And Its Clinical Significance

Objective To investigate the change of CRP and TNF-αin plasma of recurrent hepatocellular carcinoma patient before/after PMCT and discuss its clinical significance.Methods Before PMCT, there are 32 cases involved in our study including 6 of liver cirrhosis, 10 of no recurrence after resection for hepatocellular carcinoma and 16 of recurrent hepatocellular carcinoma after resection. After PMCT, 12 cases from the recurrent group are involved. ELISA is used to detect the plasma level of CRP and TNF-αin these patients.Results Before the plasma level of CRP among these three groups has no significant difference (P>0.05). The plasma level of TNF-αbetween liver cirrhosis group and no recurrence group have no significant difference (P>0.05), but it is higher in recurrence group than in no recurrence group and the different is significant (P<0.05). Compared with the plasma level of CRP before PMCT, it is significantly higher on the 1st day after PMCT (P<0.05), and has no difference on the 7th day (P>0.05). As to TNF-α, it has no difference on the 1st day (P>0.05), wherease it is significantly lower on the 7th day (P<0.05).Conclusions CRP could not be an index of monitoring recurrence of hepatocellular carcinoma after resection, wherease TNF-α, which could be used as an index to define the therapeutic effect of PMCT for recurrent hepatocellular carcinoma, could be. This therapy maybe improve immunologica status of patients with recurrent hepatocellular carcinoma.